Dr Doha Hegazy
Profiles

Dr Doha Hegazy

Post-Doctoral Research Fellow

Centre for Biomedical Research - Translational & Stratified Medicine (Peninsula Schools of Medicine and Dentistry)

Role

Hepatology Research Group Manager 
(Research & Teaching) 

Qualifications

Postgraduate Certificate in Clinical Education 
PhD Molecular Medicine 
Postgraduate Diploma in Microbiology and Public Health
Bachelor of Medicine and Surgery

Professional membership

Fellow of the higher education academy
Fellow of British Association for the studay of Liver Diseases 
Fellow of American Association for the studay of Liver Diseases

Teaching interests

  • Problem Based Learning Facilitator for Year 1 BMBS students
  • Life Science Resource Centre facilitator for Year 2 BMBS students
  • Curriculum Development for the BMBS programme
  • Special Study Unit Provider (Research in Action - Year 4 BMBS........Healthcare environment Year 1 &2 BMBS)

Research interests

Liver diseases/ Hepatitis C infection

Research degrees awarded to supervised students

Dr Prem Thurairhaja    awarded
Dr Usama Warshow     awarded 
Dr Cyril Sieberhagen     writing up
Dr Maggie Ow               awarded
Dr Evi Mandalou            writing up 
Dr Asma Ahmed            writing up 

Grants & contracts

Marry Kinross grant £286 000
NorthCott £ 6000

  

  • I.T Shawa, D.J. Felmlee, D. Hegazy,  D.A. Sheridan, m.E. Cramp. Exploration of potential mechanisms of hepatitis C virus resistance in exposed uninfected intravenous drug users. Journal of Viral hepatitis 2017
  • U. M. Warshow, A. Riva , D. Hegazy , P. H. Thurairajah, E.R. Kaminski, S. Choksh, M. E. Cramp. Cytokine profiles in high risk injection drug users suggests innate as opposed to adaptive immunity in apparent resistance to hepatitis C virus infection. Journal of Viral Hepatitis 2012
  • Grawish Mel-A, Khounganian R, Hamam MK, Zaher AR, Hegazy D, El-Negoly SA, Hassan G, Zyada MM. Altered coronal tissue of the human dental pulp in chronic hepatitis C virus infected patients. JEndodontics 2012
  • Grawish M, Zaher A, Elsabaa H, Hegazy D. Vasculitis of dental pulp associated cryoglobulinemia of hepatitis C virus patients-a case report. JEndodontics 2011
  • Knapp S, Warshow U, Ho KM, Hegazy D, Little A, Fowell A, Alexander G, Thursz M, Cramp M, Khakoo S. IL28B Polymorphism Distinguishes exposed uninfected from spontaneous resolvers of HCV infection. Gastroenterology 2011; 141 (1):320-325
  • Thrurairajah P, Hegazy D, Shaw S, Kaminski E, Cramp M. Loss of virus-specific T cell responses in HCV exposed uninfected injection drug users with drug rehabilitation and incarceration. Journal of infectious diseases, 2011; 203 (6): 847-853
  • Susanne Knapp, Usama Warshow, Doha Hegazy, Louise Brackenbury, Neil Guha, A Fowell, Ann-Margaret Little, Gracme J Alexander, Willian MC Rosenberg, Matthew E cramp, Salim Khakoo. Consistent beneficial effects of KIR2DL3 and group 1 HLA-C following exposure to hepatitis C virus. Hepatology, 2010; 51 (3): 1-8
  • Hegazy DM, Thrurairajah P, Houldsworth A, Shaw S, Kaminski E, Demaine AG Cramp ME. Interleukin 12B Gene polymorphism and apparent resistance to HCV Infection.  Clinical and Experimental Immunology, 2008; 152: 538-541
  • Thrurairajah P, Hegazy D, Shaw S, Kaminski E, Demaine A, Cramp M. Hepatitis C Virus (HCV)–Specific T Cell Responses in Injection Drug Users with Apparent Resistance to HCV Infection. Journal of infectious diseases, 2008;198:1749-1755  
  • Ironside JW, Bishop MT, Connolly K, Hegazy D, Lowrie S, Grice ML, Ritchie DL, McCardle L, Hilton DA. Variant Creutzfeldt-Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study. British Medical Journal 2006, 332 (7551): 1186-8.  
  • Hilton DA, Hegazy D. Genotyping of oligodendrogliomas in a routine diagnostic laboratory. Neuropathology and Applied Neurobiology 2005; 31 (2): 10
  • Hilton DA, Ghani  AC, Conyers L, Edwards P, McCardle L, Ritchie D, Hegazy DM, Penney M, Ironside JW. Prevalence of Lymphoreticular Prion Protein Accumulation in UK Tissue Samples. Journal of Pathology 2004; 203(3):733-9.
  • Hegazy DM, Yang BM, Peter Oates, Millward BA, Demaine AG. Aldose reductase inhibition reduces the high glucose induced increase in nuclear factor kappa B binding activity in cells from patients with diabetes mellitus. Diabetes 2003;52, suppl 1:  A730
  • Hegazy DM, O’Reilly DA, Yang BM, Hodgkinson AD, Millward BA and Demaine AG. NFκB Polymorphisms and Susceptibility to Type 1 Diabetes. Genes and Immunity 2001; 2:304-308.
  •